Dysfunction of TGF-β signaling in Alzheimer's disease

Pritam Das, Todd Golde

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Accumulation of β-amyloid peptide (Aβ) in the brain is believed to trigger a complex and poorly understood pathologic reaction that results in the development of Alzheimer's disease (AD). Despite intensive study, there is no consensus as to how Aβ accumulation causes neurodegeneration in AD. In this issue of the JCI, Tesseur et al. report that the expression of TGF-β type II receptor (TβRII) by neurons is reduced very early in the course of AD and that reduced TGF-β signaling increased Aβ deposition and neurodegeneration in a mouse model of AD (see the related article beginning on page 3060). Intriguingly, reduced TGF-β signaling in neuroblastoma cells resulted in neuritic dystrophy and increased levels of secreted Aβ. Collectively, these data suggest that dysfunction of the TGF-β/TβRII signaling axis in the AD brain may accelerate Aβ deposition and neurodegeneration.

Original languageEnglish (US)
Pages (from-to)2855-2857
Number of pages3
JournalJournal of Clinical Investigation
Volume116
Issue number11
DOIs
StatePublished - Nov 1 2006

Fingerprint

Alzheimer Disease
Brain
Neuroblastoma
Amyloid
Consensus
Neurons

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dysfunction of TGF-β signaling in Alzheimer's disease. / Das, Pritam; Golde, Todd.

In: Journal of Clinical Investigation, Vol. 116, No. 11, 01.11.2006, p. 2855-2857.

Research output: Contribution to journalArticle

Das, Pritam ; Golde, Todd. / Dysfunction of TGF-β signaling in Alzheimer's disease. In: Journal of Clinical Investigation. 2006 ; Vol. 116, No. 11. pp. 2855-2857.
@article{3cb85a41345c4baa83f07bd46766a2c1,
title = "Dysfunction of TGF-β signaling in Alzheimer's disease",
abstract = "Accumulation of β-amyloid peptide (Aβ) in the brain is believed to trigger a complex and poorly understood pathologic reaction that results in the development of Alzheimer's disease (AD). Despite intensive study, there is no consensus as to how Aβ accumulation causes neurodegeneration in AD. In this issue of the JCI, Tesseur et al. report that the expression of TGF-β type II receptor (TβRII) by neurons is reduced very early in the course of AD and that reduced TGF-β signaling increased Aβ deposition and neurodegeneration in a mouse model of AD (see the related article beginning on page 3060). Intriguingly, reduced TGF-β signaling in neuroblastoma cells resulted in neuritic dystrophy and increased levels of secreted Aβ. Collectively, these data suggest that dysfunction of the TGF-β/TβRII signaling axis in the AD brain may accelerate Aβ deposition and neurodegeneration.",
author = "Pritam Das and Todd Golde",
year = "2006",
month = "11",
day = "1",
doi = "10.1172/JCI30284",
language = "English (US)",
volume = "116",
pages = "2855--2857",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

TY - JOUR

T1 - Dysfunction of TGF-β signaling in Alzheimer's disease

AU - Das, Pritam

AU - Golde, Todd

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Accumulation of β-amyloid peptide (Aβ) in the brain is believed to trigger a complex and poorly understood pathologic reaction that results in the development of Alzheimer's disease (AD). Despite intensive study, there is no consensus as to how Aβ accumulation causes neurodegeneration in AD. In this issue of the JCI, Tesseur et al. report that the expression of TGF-β type II receptor (TβRII) by neurons is reduced very early in the course of AD and that reduced TGF-β signaling increased Aβ deposition and neurodegeneration in a mouse model of AD (see the related article beginning on page 3060). Intriguingly, reduced TGF-β signaling in neuroblastoma cells resulted in neuritic dystrophy and increased levels of secreted Aβ. Collectively, these data suggest that dysfunction of the TGF-β/TβRII signaling axis in the AD brain may accelerate Aβ deposition and neurodegeneration.

AB - Accumulation of β-amyloid peptide (Aβ) in the brain is believed to trigger a complex and poorly understood pathologic reaction that results in the development of Alzheimer's disease (AD). Despite intensive study, there is no consensus as to how Aβ accumulation causes neurodegeneration in AD. In this issue of the JCI, Tesseur et al. report that the expression of TGF-β type II receptor (TβRII) by neurons is reduced very early in the course of AD and that reduced TGF-β signaling increased Aβ deposition and neurodegeneration in a mouse model of AD (see the related article beginning on page 3060). Intriguingly, reduced TGF-β signaling in neuroblastoma cells resulted in neuritic dystrophy and increased levels of secreted Aβ. Collectively, these data suggest that dysfunction of the TGF-β/TβRII signaling axis in the AD brain may accelerate Aβ deposition and neurodegeneration.

UR - http://www.scopus.com/inward/record.url?scp=33750591504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750591504&partnerID=8YFLogxK

U2 - 10.1172/JCI30284

DO - 10.1172/JCI30284

M3 - Article

C2 - 17080189

AN - SCOPUS:33750591504

VL - 116

SP - 2855

EP - 2857

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 11

ER -